Scapa Healthcare recently announced it has completed the acquisition of the Systagenix manufacturing facility located in Gargrave, England, from Acelity. As part of the transaction, the manufacturing operations, sterilization services, warehouse facilities, R&D and regulatory support functions located in Gargrave have been transferred to Scapa Healthcare.
Scapa Healthcare and Acelity have entered into a long-term exclusive manufacturing and supply agreement, in which Scapa Healthcare will reportedly continue manufacturing the KCI advanced wound-dressings portfolio manufactured in Gargrave.
“The acquisition of the Gargrave site positions Scapa Healthcare as a leading business-to-business manufacturer of medical devices,” said Joe Davin, president Scapa Healthcare. “The new facility is well invested to support new product development and manufacturing not only for wound care products, but also consumer wellness and wearable fixation devices. We believe this represents a great opportunity for our customers as we remain committed to be the trusted strategic outsource partner of choice for the markets we serve.”
For more information, visit www.scapahealthcare.com.